German private‑equity firm Mutares has signed a deal to carve out the acrylic business of UK‑listed Synthomer. The transaction will spin off the segment that produces acrylic acids and esters, creating a dedicated platform for Mutares’ Chemicals & Materials portfolio. Closing is slated for the end of Q3 2026, subject to customary regulatory approvals.

The carved‑out unit generated roughly €110 million in revenue in 2025, indicating a modest but stable cash flow stream. By acquiring the business, Mutares aims to leverage its operational expertise to drive margin improvement and possibly roll‑up adjacent specialty chemical assets. The move diversifies the firm’s exposure beyond its existing industrial holdings.

Investors will watch how the carve‑out impacts Mutares’ earnings, as the added revenue could lift its top line while the restructuring may generate one‑off costs. The deal underscores a broader trend of private‑equity firms targeting niche chemical producers to build scale. Mutares now controls a standalone acrylic platform ready for strategic growth.

The carve‑out also removes a non‑core segment from Synthomer plc, allowing the remaining company to focus on its core polymer businesses. Analysts note that shedding the acrylic line could improve Synthomer’s balance sheet and free cash flow, potentially supporting dividend policy or debt reduction. The split creates two more focused entities for investors.